Current Headlines

  1. ABL Successfully Completes Drug Product Manufacture Of Ebola Vaccine For Clinical Trial

    ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT)

  2. Elsevier Solutions Address The Challenges Of Lead Optimization In Early Drug Discovery

    Improved content discoverability via Reaxys® Medicinal Chemistry combined with data integration capabilities allow chemists to identify and optimize promising lead candidates

  3. CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform

    CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today unveiled its proprietary LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage the Company's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies

  4. Fast Liquid Transfer Down To Picoliter Levels With Tecan’s D300e

    Tecan has introduced the D300e Digital Dispenser* for applications that need faster, reliable dispensing down to picoliter volumes.

  5. Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

    Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015

  6. Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma

    Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma

  7. MM-398 Receiving The Priority Review Designation By US FDA For New Drug Application And The Acceptance Of Market Authorization Application By EMA In Post-Gemcitabine Metastatic Pancreatic Cancer

    PharmaEngine, Inc. (TWO: 4162) announced that (1) its license partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), has received the notification from the US Food and Drug Administration (FDA) for the acceptance and the grant of the priority review designation for their New Drug Application (NDA); and (2) its sublicense partner, Baxalta Incorporated, a wholly owned subsidiary of Baxter International Inc. (NYSE: BAX) has received the acceptance of Market Authorization Application (MAA) from the European Medicines Agency (EMA), of MM-398 (irinotecan liposome injection, also known as "nal-IRI,") in the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy

  8. DynaMed Plus™ Now Features Micromedex® Evidence-Based Content From Truven Health Analytics™

    EBSCO Health and Truven Health Analytics™ today announced that Micromedex® Medication Management and Lab Recommendation resources are now featured in DynaMed Plus™, a cross-platform evidence-based clinical decision support tool for physicians and other medical professionalsintroduced earlier this month

  9. Genedata And IntelliCyt Forge Alliance To Transform Cell-Based Screening In Drug Discovery

    Genedata and IntelliCyt today announced an alliance that brings together the market-leading strengths of each company to transform screening of suspension cells

  10. Asymmetrex Introduces ‘The Third Dimension Of Time’ To 3D Cell Modelers At The 14th Annual World Preclinical Congress In Boston

    The 3D tissue modelers in attendance for WPC 2015share a common goal

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.